Sensitization from transfusion in patients awaiting primary kidney transplant

Nephrology Dialysis Transplantation

Volumn 28, Issue 11, 2013, Pages 2908-2918

  Yabu, Julie M ^a   Anderson, Matthew W ^b,c   Kim, Deborah ^d   Bradbury, Brian D ^d   Lou, Calvin D ^b   Petersen, Jeffrey ^d   Rossert, Jerome ^d   Chertow, Glenn M ^a   Tyan, Dolly B ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

^c BLOOD RESEARCH INSTITUTE   (United States)

^d AMGEN INC   (United States)

Author keywords

Calculated panel reactive antibody; HLA antibody; Kidney transplantation; Sensitization; Transfusion

Indexed keywords

HLA ANTIBODY; PANEL REACTIVE ANTIBODY;

ADULT; ANTIBODY PRODUCTION; ANTIGEN SENSITIZATION; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANALYSIS; GRAFT RECIPIENT; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEAN FLUORESCENCE INTENSITY; MIDDLE AGED; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SENSITIZATION;

CALCULATED PANEL REACTIVE ANTIBODY; HLA ANTIBODY; KIDNEY TRANSPLANTATION; SENSITIZATION; TRANSFUSION;

ANTIBODIES; ANTIBODY FORMATION; BLOOD TRANSFUSION; CROSS-OVER STUDIES; FEMALE; HLA ANTIGENS; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; WAITING LISTS;

EID: 84890045873     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft362     Document Type: Article

References (45)

1. Port FK, Wolfe RA, Mauger EA et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA 1993; 270: 1339-1343
2. Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725-1730
3. Lee AJ, Morgan CL, Conway P et al. Characterisation and comparison of health-related quality of life for patients with renal failure. Curr Med Res Opin 2005; 21: 1777-1783
4. US Renal Data System. USRDS 2012 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, Vol. 2, Chapter 2 Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012
5. Network OPTN. Scientific Registry of Transplant Recipients: OPTN: Data 2011. http://optn.transplant.hrsa.gov/ (September 2012, date last accessed)
6. Locatelli F, Pisoni RL, Combe C et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2004; 19: 121-132
7. McClellan WM, Flanders WD, Langston RD et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 2002; 13: 1928-1936
8. Eschbach JW. Current concepts of anemia management in chronic renal failure: impact of NKF-DOQI. Semin Nephrol 2000; 20: 320-329
9. Churchill DN, Taylor DW, Cook RJ et al. Canadian hemodialysis morbidity study. Am J Kidney Dis 1992; 19: 214-234
10. Ibrahim HN, Ishani A, Foley RN et al. Temporal trends in red blood transfusion among US dialysis patients, 1992-2005. Am J Kidney Dis 2008; 52: 1115-1121
11. Pfeffer MA, Burdmann EA, Chen CY et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 2019-2032
12. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098
13. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084
14. Hebert PL, Geiss LS, Tierney EF et al. Identifying persons with diabetes using medicare claims data. Am J Med Qual 1999; 14: 270-277
15. Eschbach JW, Haley NR, Adamson JW. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin. Contrib Nephrol 1990; 78: 24-36; discussion 7
16. Opelz G, Graver B, Mickey MR et al. Lymphocytotoxic antibody responses to transfusions in potential kidney transplant recipients. Transplantation 1981; 32: 177-183
17. Scornik JC, PfaffWW, Howard RJ et al. Increased antibody responsiveness to blood transfusions in pediatric patients. Transplantation 1994; 58: 1361-1365
18. Karpinski M, Pochinco D, Dembinski I et al. Leukocyte reduction of red blood cell transfusions does not decrease allosensitization rates in potential kidney transplant candidates. J Am Soc Nephrol 2004; 15: 818-824
19. Scornik JC, Meier-Kriesche HU. Blood transfusions in organ transplant patients: mechanisms of sensitization and implications for prevention. Am J Transplant 2011; 11: 1785-1791
20. Balasubramaniam GS, Morris M, Gupta A et al. Allosensitization rate of male patients awaiting first kidney grafts after leukodepleted blood transfusion. Transplantation 2012; 93: 418-422
21. Cecka JM. Calculated PRA (CPRA): the new measure of sensitization for transplant candidates. Am J Transplant 2010; 10: 26-29
22. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipi-ents (SRTR). OPTN/ SRTR 2010 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, 2011
23. USRDS. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2010
24. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J Transplant 2004; 4: 438-443
25. Terasaki PI, Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. Transplantation 2005; 80: 1194-1197
26. Lefaucheur C, Loupy A, Hill GS et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-1406
27. Ibrahim HN, Skeans MA, Li Q et al. Blood transfusions in kidney transplant candidates are common and associated with adverse outcomes. Clin Transplant 2011; 25: 653-659
28. Dausset J. Indications for transfusion with concentrated or washed erythrocytes. Concours Med 1954; 76: 2975-2977
29. Murphey CL, Forsthuber TG. Trends in HLA antibody screening and identification and their role in transplantation. Expert Rev Clin Immunol 2008; 4: 391-399
30. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337: 1861-1869
31. Fisher M, Chapman JR, Ting A et al. Alloimmunisation to HLA antigens following transfusion with leucocyte-poor and purified platelet suspensions. Vox Sang 1985; 49: 331-335
32. Everett ET, Kao KJ, Scornik JC. Class I HLA molecules on human erythrocytes. Quantitation and Transfusion Effects. Transplantation 1987; 44: 123-129
33. Morales-Buenrostro LE, Terasaki PI, Marino-Vazquez LA et al. "Natural" human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008; 86: 1111-1115
34. Alberu J, Morales-Buenrostro LE, de Leo C et al. A nonallogeneic stimulus triggers the production of de novo HLA antibodies in healthy adults. Transpl Immunol 2007; 18: 166-171
35. Troidle L, Eisen T, Pacelli L et al. Complications associated with the development of bacteremia with staphylococcus aureus. Hemodial Int 2007; 11: 72-75
36. Locke JE, Zachary AA, Warren DS et al. Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant 2009; 9: 2136-2139
37. Triulzi DJ, Kleinman S, Kakaiya RM et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion 2009; 49: 1825-1835
38. Organ Procurement and Transplantation Network (OPTN) Proposal to Substantially Revise the National Kidney Allocation System. 2012. http://optn.transplant.hrsa.gov/PublicComment/pubcommentPropSub-311.pdf. (17 June 2013, date last accessed)
39. Despotis GJ, Zhang L, Lublin DM. Transfusion risks and transfusion-related pro-inflammatory responses. Hematol Oncol Clin North Am 2007; 21: 147-161
40. Carson JL, Altman DG, Duff A et al. Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair. Transfusion 1999; 39: 694-700
41. Epstein JS, Holmberg JA. Progress in monitoring blood safety. Transfusion 2010; 50: 1408-1412
42. Zou S, Dorsey KA, Notari EP et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50: 1495-1504
43. Stramer SL, Hollinger FB, Katz LM et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49 (Suppl 2): 1s-29s
44. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical practice guideline for anemia in chronic kidney disease. Kidney Int 2012; 2 (Suppl 2): 279-335
45. Circular of Information for the Use of Human Blood and Blood Components. 2009. http://www.aabb.org/resources/bct/pages/ aabb-coi.aspx (July 2013, date last accessed)